文献速递湿疹皮炎与荨麻疹

Difamilast软膏治疗成人特应性皮炎:3期随机双盲对照试验

Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2021-10-25

这项3期随机双盲试验纳入日本15-70岁、IGA评分为2或3的成人特应性皮炎患者,比较1% Difamilast软膏(n=182)与赋形剂(n=182)每日两次外涂4周的疗效。第4周IGA成功率为38.46%对12.64%(P<.0001),EASI多项改善率同趋势,不良事件多为轻中度且Difamilast组更少。

要点

  • 1% Difamilast软膏每日两次外用4周,IGA成功率为38.46%,显著高于赋形剂的12.64%。
  • EASI较基线改善从第1周起即显著优于赋形剂,并持续至第4周。
  • 治疗中出现的不良事件多为轻中度,Difamilast组发生频率低于赋形剂组。

核心结论

  • 1% Difamilast软膏在成人日本特应性皮炎患者中优于赋形剂,且安全性良好。

研究设计与样本

  • 3期随机双盲赋形剂对照试验,纳入15-70岁、IGA评分为2或3的患者,1% Difamilast组n=182,赋形剂组n=182,每日两次外用4周。

主要发现

  • 第4周IGA成功率(IGA 0或1且改善≥2级)为38.46%对12.64%,P<.0001。
  • 第4周EASI改善≥50%、≥75%、≥90%的成功率呈相同趋势。
  • 1% Difamilast自第1周至第4周EASI总体评分较基线的平均改善百分比显著优于赋形剂。
  • 治疗中出现的不良事件多为轻中度,Difamilast组更少。

关键数值与推荐

  • 主要终点为第4周IGA成功率,定义为IGA评分0或1且较基线改善≥2级。
  • 1% Difamilast组IGA成功率为38.46%,赋形剂组为12.64%,P<.0001。

临床怎么用

  • 对于IGA评分为2或3的成人特应性皮炎患者,可考虑每日两次外用1% Difamilast软膏4周。
  • 疗效评估可结合IGA成功率与EASI改善率,并关注用药后不良事件。

局限性

  • 研究治疗时间仅限4周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Difamilast is a selective phosphodiesterase 4 inhibitor. Phosphodiesterase 4 is involved in cytokine production linked with inflammatory disorders, including atopic dermatitis. OBJECTIVE: To demonstrate the superiority of difamilast ointment 1% to vehicle in adult Japanese patients with atopic dermatitis. METHODS: In this phase 3, randomized, double-blind trial, patients aged 15-70 years with an investigator global assessment score of 2 or 3 received topical difamilast ointment 1% (n = 182) or a vehicle (n = 182) twice daily for 4 weeks. RESULTS: The success rate in investigator global assessment score at week 4 (primary endpoint)-the percentage of patients achieving an investigator global assessment score of 0 or 1 with ≥2-grade improvement-was significantly higher with 1% difamilast than with the vehicle (38.46% vs 12.64%, respectively, P < .0001). The success rates in ≥50%, ≥75%, and ≥90% improvement in overall eczema area and severity index score at week 4 followed the same trend. Difamilast at 1% provided significant mean percent improvement from baseline in overall eczema area and severity index score versus vehicle from week 1 to 4. Treatment-emergent adverse events were mostly mild or moderate and less frequent with difamilast. LIMITATIONS: Study treatment was limited to 4 weeks. CONCLUSION: Difamilast ointment 1% demonstrated superiority to the vehicle and favorable safety in adult Japanese patients with atopic dermatitis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Saeki H, Ito K, Yokota D, et al. Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2021. PMID: 34710557. doi:10.1016/j.jaad.2021.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。